Strategic Partnership with A. Menarini Diagnostics to Launch iCan CGM in Europe 

Sinocare, a leading healthcare China company, has announced a strategic partnership and signed an exclusive distribution agreement with A. Menarini Diagnostics. The agreement marks a significant milestone as Sinocare’s Continuous Glucose Monitoring (CGM) products will enter over 20 jurisdictions in Europe under a co-branded label. A. Menarini Diagnostics will register, promote, distribute, and market Sinocare CGM products within reimbursed markets.

A Synergistic Collaboration 

Sinocare’s advanced third-generation direct electronic transfer technology underpins its CGM product, delivering excellent accuracy, stability, and anti-interference capabilities. Widely acclaimed since its launch, this technology underscores Sinocare's commitment to improving diabetes management. 

A. Menarini Diagnostics, with over 45 years of expertise in medical diagnostics, is part of the renowned Menarini Pharmaceutical Group, which operates in more than 140 countries. This partnership brings together Sinocare's innovative technology and A. Menarini Diagnostics’s deep commercialization experience, fostering more opportunities for advancing diabetes care across Europe.

Bringing Advanced Diabetes Care to More Patients 

"The partnership with A. Menarini Diagnostics is a significant milestone in our mission to make our CGM Systems widely accessible to people with diabetes," stated Dr. Jiangfeng Fei, Global Head of Sinocare CGM Business. "We are pleased to enter into a strategic partnership with A. Menarini Diagnostics, a leader in the healthcare industry, to bring this innovative diabetes technology to a broader audience."

A. Menarini Diagnostics shares this enthusiasm for the collaboration and its potential impact on diabetes care. "Securing exclusive rights for the distribution and marketing of this Sinocare third Generation CGM System across various countries aligns with our commitment to providing innovative healthcare solutions," commented Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics. " We are confident that this long-term partnership will meet the growing demand for advanced diabetes care."

Positioning for Growth in Europe’s Expanding Market 

Europe, the world’s second-largest CGM market, continues to grow as reimbursement systems evolve and patient awareness increases. Meanwhile, Sinocare’s proprietary technology, robust quality control systems, and large-scale automated manufacturing provide a strong foundation for cost-efficient production and rapid market expansion.

Sinocare’s strategic alliance with A. Menarini Diagnostics is expected to significantly enhance the availability of Sinocare’s CGM products across Europe, positioning it to thrive in this competitive landscape. 

About A. Menarini Diagnostics 

A. Menarini Diagnostics is a leading healthcare company dedicated to providing innovative solutions for better health outcomes through advanced diagnostic tools and technologies. The company has more than 45 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world. A. Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, with more than 17,000 employees and 2023 turnover of € 4.375 billion.

About Sinocare 

Founded in 2002, Sinocare Inc. was the first blood glucose meter company to be listed in China. With a strong presence in Asia and the U.S., Sinocare is the largest manufacturer of blood glucose monitoring devices in Asia and the fourth largest globally, as well as one of the leading POCT companies worldwide.  It continues to lead the way in biosensing innovation on the international stage, advancing its mission to be the global leading diabetes digital management expert.